acneform


Also found in: Dictionary.

ac·ne·form

(ak'nē-fōrm),
Resembling acne.
Synonym(s): acneiform

acneform

[ak′nifôrm]
resembling acne. Also acneiform [aknē′əfôrm] .

ac·ne·form

, acneiform (ak'nē-fōrm, ak-nē'i-fōrm)
Resembling acne.

acneiform

, acneform (ak-nē′ĭ-form″) (ak-nē′form″) [ acne + -form]
Resembling acne.
References in periodicals archive ?
Out of 48 ACDRs reported in prospective study, most common was acneform eruption (25.
The most common drugs responsible for ACDRs in prospective study were betamethasone, isoniazid and rifampicin for acneform eruption, while metronidazole and paracetamol for FDE.
The most common drug groups responsible were antimalarial and fluroquinolones for FDE [Figure-4], while acneform eruption was mainly caused by systemic steroids.
Acneform rash usually developed within the first two weeks of therapy and resolved in a majority of the patients after cessation of treatment, although in nearly half, the event continued beyond 28 days
The most frequent adverse events seen in patients with metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence 50%) were acneform rash (88%), asthenia/malaise (73%), diarrhea (72%), and nausea (55%).
The most frequent adverse events seen in patients with metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence greater than or equal to 50%) were acneform rash (88%), asthenia/malaise (73%), diarrhea (72%), and nausea (55%).
The most frequent adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX in combination with radiation therapy (n=208) versus radiation alone (n=212) (incidence =50%) were acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), and asthenia (56%/49%).
The most frequent adverse events seen in patients with metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence = 50%) were acneform rash (88%), asthenia/malaise (73%), diarrhea (72%), and nausea (55%).
The most frequent adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX in combination with radiation therapy (n=208) versus radiation alone (n=212) (incidence [greater than or equal to]50%) were acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), and asthenia (56%/49%).
The most frequent adverse events seen in patients with metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence [greater than or equal to] 50%) were acneform rash (88%), asthenia/malaise (73%), diarrhea (72%), and nausea (55%).
The most frequent adverse events seen in patients with metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence [greater than or equal to]50%) were acneform rash (88%), asthenia/malaise (73%), diarrhea (72%), and nausea (55%).
For example, many patients treated with EGFR inhibitors develop dermatological toxicity, including skin drying, fissuring, and acneform rash that may cause the reduction, interruption or discontinuation of treatment.